Atezolizumab plus chemotherapy regimen safe, effective for squamous cell anal carcinoma
Click Here to Manage Email Alerts
Atezolizumab plus a modified docetaxel, cisplatin and 5-fluorouracilregimen is a safe and effective first-line treatment for locally advanced squamous cell anal carcinoma, according to research presented at 2022 ASCO Annual Meeting.
Anal carcinomas make up 2.7% of gastrointestinal cancers, which has increased over time, according to the study's authors.
"The combination of [a modified docetaxel, cisplatin and 5-fluorouracil] and immunotherapy is safe; however, this trial did not meet its primary endpoint of 1-year PFS rate superior to 46%," Stefano Kim, MD, medical oncologist at University Hospital of Besançon, France, said during his oral abstract presentation.
The results of the SCARCE trial were consistent with previous research into modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimens.
This is the first study to evaluate the combination of chemotherapy and immunotherapy in patients with advanced squamous cell anal carcinoma, Kim said. The multicentric study split patients into two arms. Arm A consisted of 64 patients who received 800 mg atezolizumab (Tecentriq, Genentech) dosed every other week for up to a year plus eight cycles of mDCF. The 33 patients in Arm B received only eight cycles of mDCF.
The PFS rate for patients in Arm A, was lower than 46% at 44.2%, so it was considered statistically noninteresting, Kim said.
In addition, patients in Arm A had an objective response rate of 74.6% and a 12-month OS rate of 77.7%. These outcomes were like outcomes previously reported in other studies, including Epitopes-HPV02, “sustaining the high level of mDCF efficacy in squamous cell anal carcinoma,” Kim said.
The centralized analysis and quality-of-life analysis are still pending, Kim said.
Collapse
Read more about
Click Here to Manage Email Alerts